-
公开(公告)号：US20070027192A1
公开(公告)日：2007-02-01
申请号：US11493155
申请日：2006-07-26
IPC分类号： A61K31/44 , C07D213/72
CPC分类号： C07D213/74
摘要： A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enatiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
摘要翻译： 选自式（I）的化合物：其中：n表示1至6的整数，其中R 1和R 2均表示氢原子，（C C 1 -C 6烷基或芳基 - （C 1 -C 6 -C 6）烷基，R R 3和R 4代表氢原子或（C 1 -C 6 -C 6）烷基， R 5和R 6表示氢原子或（C 1 -C 6 -C 6）烷基，卤素，羟基， （C 1 -C 6 -C 6）烷氧基，氰基，硝基，（C 2 -C 6 -C 6）酰基， （C 1 -C 6 -C 6）烷氧基羰基，（C 1 -C 6 -C 6）三卤代烷基或（C
-
2.发明申请Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them 审中-公开多取代的吡啶基氨基亚烷基 - 和吡啶基氧亚烷基 - 环丙胺化合物，其制备方法和含有它们的药物组合物公开(公告)号：US20100317698A1
公开(公告)日：2010-12-16
申请号：US12223311
申请日：2007-01-30
IPC分类号： A61K31/444 , C07D213/65 , C07D401/04 , C07D401/10 , C07D213/72 , A61K31/4439 , A61K31/4418 , A61P25/28 , A61P25/00 , A61P25/04 , A61P25/16 , A61P25/34
CPC分类号： C07D401/10 , C07D213/65
摘要： Compounds of formula (I): wherein: n represents an integer of from 1 to 6 inclusive, X represents an oxygen atom or an NR6 group, Y represents a carbon atom or a nitrogen atom, Z represents a carbon atom or a nitrogen atom, R1 and R2 represent a hydrogen atom or an alkyl or arylalkyl group, R3 and R4 represent a hydrogen atom or an alkyl group, R5 represents a hydrogen atom or an alkyl, halogen, hydroxy, alkoxy, cyano, nitro, acyl, alkoxycarbonyl, trihaloalkyl, trihaloalkoxy or optionally substituted amino group, R6 represents a hydrogen atom or an alkyl or arylalkyl group, Ra, Rb, Rc, Rd and Re are as defined in the description. Medicinal products containing the same which are useful as specific nicotinic ligands of α4β2 receptors.
摘要翻译： 式（I）化合物：其中：n表示1〜6的整数，X表示氧原子或NR 6基，Y表示碳原子或氮原子，Z表示碳原子或氮原子， R1和R2表示氢原子或烷基或芳烷基，R3和R4表示氢原子或烷基，R5表示氢原子或烷基，卤素，羟基，烷氧基，氰基，硝基，酰基，烷氧基羰基，三卤代烷基 ，三卤代烷氧基或任选取代的氨基，R 6表示氢原子或烷基或芳基烷基，R a，R b，R c，R d和R e如说明书中所定义。 含有它们的药物，其可用作α4和bgr2受体的特异性烟碱配体。
-
公开(公告)号：US20080146621A1
公开(公告)日：2008-06-19
申请号：US12070163
申请日：2008-02-15
CPC分类号： C07D213/74
摘要： A compound selected from those of formula (1): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
摘要翻译： 选自式（1）的化合物：其中：n表示1〜6的整数，R 1和R 2表示氢原子，（C C 1 -C 6烷基或芳基 - （C 1 -C 6 -C 6）烷基，R R 3和R 4代表氢原子或（C 1 -C 6 -C 6）烷基， R 5和R 6表示氢原子或（C 1 -C 6 -C 6）烷基，卤素，羟基， （C 1 -C 6 -C 6）烷氧基，氰基，硝基，（C 2 -C 6 -C 6）酰基， （C 1 -C 6 -C 6）烷氧基羰基，（C 1 -C 6 -C 6）三卤代烷基或（C
-
公开(公告)号：US6150358A
公开(公告)日：2000-11-21
申请号：US460596
申请日：1999-12-14
IPC分类号： A61K31/5377 , A61P25/00 , A61P25/28 , A61P39/06 , A61P43/00 , C07D339/04 , C07D413/12
CPC分类号： C07D339/04
摘要： A compound of formula (I): ##STR1## wherein Ra represents linear or branched (C.sub.1 -C.sub.8)alkylene,Rb represents single bond, or linear or branched (C.sub.1 -C.sub.6)alkylene,Z represents thiocarbamate, or thioamide, each being optionally substituted,T represents optionally substituted morpholino,its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of disease for which the use of anti-oxidation agent is required.
摘要翻译： 式（I）化合物：其中Ra表示直链或支链（C1-C8）亚烷基，Rb表示单键，或直链或支链（C1-C6）亚烷基，Z表示硫代氨基甲酸盐或硫代酰胺，各自任选被取代，T 表示任选取代的吗啉代，其异构体和药学上可接受的酸或碱加成盐，以及含有该取代基的药物制剂，其可用于治疗需要使用抗氧化剂的疾病。
-
公开(公告)号：US5478853A
公开(公告)日：1995-12-26
申请号：US376052
申请日：1995-01-20
申请人： Gilbert Regnier , Yves Charton , Jacques Duhault , Joseph Espinal
发明人： Gilbert Regnier , Yves Charton , Jacques Duhault , Joseph Espinal
IPC分类号： C07D277/34 , C07D417/10 , C07D417/12 , A61K31/425
CPC分类号： C07D277/34 , C07D417/10 , C07D417/12
摘要： The compounds are 5-(4-substituted benzyl)thiazolidine-2,4-diones, enantiomers, diastereoisomers and pharmaceutically tolerable salts thereof, useful for treating conditions of insulin-resistance and/or non insulin-dependent diabetes.A compound disclosed is: 5-{4-[2-(2-methoxy-5-chlorobenzamido)ethyl]benzyl}thiazolidine-2,4-dione.
摘要翻译： 该化合物是可用于治疗胰岛素抵抗和/或非胰岛素依赖型糖尿病的病症的5-（4-取代苄基）噻唑烷-2,4-二酮，其对映异构体，非对映异构体和药学上可接受的盐。 公开的化合物是：5- {4- [2-（2-甲氧基-5-氯苯甲酰氨基）乙基]苄基}噻唑烷-2,4-二酮。
-
公开(公告)号：US5958938A
公开(公告)日：1999-09-28
申请号：US120899
申请日：1998-07-22
IPC分类号： C07D519/00 , A61K31/435 , C07D471/04
CPC分类号： C07D519/00
摘要： Compounds of the formula: ##STR1## in which R.sub.1, R.sub.2, A and B are as defined in the description, their optical isomers, N-oxides and addition salts with a phar-maceutically acceptable acid, and their use as anti-tumor agents.
摘要翻译： 下式的化合物：其中R1，R2，A和B如说明书中所定义，它们的光学异构体，N-氧化物和药学上可接受的酸的加成盐及其作为抗肿瘤剂的用途。
-
公开(公告)号：US5919791A
公开(公告)日：1999-07-06
申请号：US998922
申请日：1997-12-29
申请人： Claude Guillonneau , Emile Bisagni , Yves Charton , Ghanem Atassi , Alain Pierre , Stephane Leonce
发明人： Claude Guillonneau , Emile Bisagni , Yves Charton , Ghanem Atassi , Alain Pierre , Stephane Leonce
IPC分类号： A61K31/47 , A61P35/00 , A61P43/00 , C07D471/04 , A01N43/42 , C07D471/00
CPC分类号： C07D471/04
摘要： The compounds of formula: ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and A are as defined in the description, their optical isomers and N-oxides and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as anti-tumour agents.
摘要翻译： 下式的化合物：其中：R1，R2，R3，R4，R5，R6，R7和A如说明书中所定义，它们的光学异构体和N-氧化物及其与药学上可接受的酸或碱的加成盐，以及 它们用作抗肿瘤剂。
-
公开(公告)号：US20070027191A1
公开(公告)日：2007-02-01
申请号：US11493070
申请日：2006-07-26
IPC分类号： A61K31/4412 , C07D213/70
CPC分类号： C07D213/65
摘要： A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom, or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl, (C1-C6)trihaloalkoxy or optionally substituted amino group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
摘要翻译： 选自式（I）的化合物：其中：n表示1至6的整数，其中R 1和R 2均表示氢原子，（C C 1 -C 6烷基或芳基 - （C 1 -C 6 -C 6）烷基，R R 3和R 4代表氢原子或（C 1 -C 6 -C 6）烷基， R 5和R 6表示氢原子或（C 1 -C 6 -C 6）烷基，卤素，羟基（C 1 -C 6） ，（C 1 -C 6 -C 6）烷氧基，氰基，硝基，（C 2 -C 6 -C 6）酰基 （C 1 -C 6 -C 6）烷氧基羰基，（C 1 -C 6 -C 6）三卤代烷基，（C 1 -C 6 - 三卤代烷氧基或任选取代的氨基，其对映异构体，非对映异构体及其药学上可接受的酸或碱的其它盐。 含有该药物的药物可用于治疗需要α4β2受体特异性烟碱配体的病症。
-
公开(公告)号：US20050032845A1
公开(公告)日：2005-02-10
申请号：US10929928
申请日：2004-08-30
IPC分类号： C07D295/08 , A61K31/10 , A61K31/13 , A61K31/133 , A61K31/15 , A61K31/16 , A61K31/215 , A61K31/22 , A61K31/221 , A61K31/223 , A61K31/27 , A61K31/40 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/445 , A61K31/455 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/28 , A61P25/34 , A61P29/00 , A61P29/02 , A61P43/00 , C07C62/02 , C07C209/00 , C07C211/37 , C07C213/00 , C07C213/02 , C07C213/06 , C07C215/20 , C07C215/42 , C07C217/44 , C07C217/52 , C07C219/18 , C07C219/20 , C07C219/24 , C07C269/00 , C07C269/02 , C07C271/12 , C07C271/22 , C07C271/24 , C07C271/34 , C07C319/14 , C07C321/28 , C07C323/26 , C07C323/33 , C07D213/30 , C07D213/38 , C07D213/53 , C07D213/65 , C07D213/70 , C07D213/80 , C07D213/803 , C07D295/096 , C07D417/12
CPC分类号： C07D213/70 , C07C217/44 , C07C217/52 , C07C219/18 , C07C219/24 , C07C271/12 , C07C271/34 , C07C323/26 , C07C2601/02 , C07D213/65 , C07D295/096
摘要： A compound selected from those of formula (1): wherein: p represents an integer of from 0 to 6 inclusive, n represents an integer of from 0 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, alkyl, aryl and arylalkyl, or R1+R2 form together with nitrogen carrying them saturated, monocyclic, or bicyclic system, X represents a group selected from oxygen, sulphur, a group —CH═CH—, methylene, a group of formula —HC═N—O— and a group of formula —O—CH2—CH═CH—, in which groups oxygen is linked to Y of the compounds of formula (I), Y represents a group selected from aryl, heteroaryl, arylalkyl, heteroarylalkyl, —C(O)-A, and —C(S)-A, A represents a group selected from alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, and NR3R4 wherein R3, and R4 represent a group selected from hydrogen, alkyl, aryl, and arylalkyl, or R3+R4 form together with nitrogen carrying them monocyclic, or bicyclic (C3-C10) system, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific nicotinic ligand of α4β2 receptors.
摘要翻译： 选自式（1）的化合物：其中：p表示0〜6的整数，n表示0〜6的整数，R1，R2表示选自氢，烷基，芳基和 芳基烷基或R 1 + R 2与带有饱和，单环或双环体系的氮一起形成，X表示选自氧，硫，基团-CH = CH-，亚甲基，式-HC = NO-的基团和 式-O-CH2-CH = CH-的基团，其中氧与式（I）化合物的Y连接，Y表示选自芳基，杂芳基，芳烷基，杂芳基烷基，-C（O） -A和-C（S）-A，A表示选自烷基，芳基，杂芳基，芳基烷基，杂芳基烷基和NR 3 R 4中的基团，其中R 3，R 4表示选自氢，烷基，芳基和芳烷基的基团，或 R3 + R4与携带它们单环或二环（C 3 -C 10）体系的氮一起形成，其异构体及其加成盐与药学上可接受的 酸或碱，以及含有它们的药物可用作α4β2受体的特异性烟碱配体。
-
公开(公告)号：US6162811A
公开(公告)日：2000-12-19
申请号：US999364
申请日：1997-12-29
申请人： Claude Guillonneau , Yves Charton , Emile Bisagni , Ghanem Atassi , Alain Pierre , Nicolas Guilbaud
发明人： Claude Guillonneau , Yves Charton , Emile Bisagni , Ghanem Atassi , Alain Pierre , Nicolas Guilbaud
IPC分类号： A61K31/435 , A61P35/00 , C07D471/04 , A61K31/4745
CPC分类号： C07D471/04
摘要： The compounds of formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and A are as defined in the description, their optical isomers and N-oxides, and pharmaceutically acceptable addition salts thereof with an acid or base, and the use thereof as anti-tumor agents.
摘要翻译： 下式的化合物：其中R1，R2，R3，R4，R5，R6，R7，R8和A如说明书中所定义，它们的光学异构体和N-氧化物及其与酸或碱的药学上可接受的加成盐， 及其作为抗肿瘤剂的用途。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.016 秒)